Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery
- First Online:
- 371 Downloads
Multi-targeted hybrids combine two drugs in a single molecule to have greater medicinal effects than its individual components. Recently, a number of anti-cancer drug candidates such as CUDC-101 (Curis) have been designed based on linking properly two selected pharmacophores endowed with activity against different therapeutic targets.
Unable to display preview. Download preview PDF.
- Cai, X., Zhai, H.-X., Wang, J., Forrester, J., Qu, H., Yin, L., Lai, C.-J., Bao, R., and Qian, C., Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J. Med. Chem., 53, 2000–2009 (2010).PubMedCrossRefGoogle Scholar
- Lai, C. J., Bao, R., Tao, X., Wang, J., Atoyan, R., Qu, H., Wang, D. G., Yin, L., Samson, M., Forrester, J., Zifcak, B., Xu, G. X., DellaRocca, S., Zhai, H. X., Cai, X., Munger, W. E., Keegan, M., Pepicelli, C. V., and Qian, C., CUDC-101, a multitargeted Inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res., 70, 3647–3656 (2010).PubMedCrossRefGoogle Scholar
- Lehár, J., Krueger, A. S., Averyl, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., Lee, M. S., Zimmermann, G. R., and Borisy, A. A., Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol., 27, 659–666 (2009).PubMedCrossRefGoogle Scholar
- Mahboobi, S., Dove, S., Sellmer, A., Winkler, M., Eichhorn, E., Pongratz, M., Ciossek, T., Baer, T., Maier, T., and Beckers, T., Design of chimeric histone deacetylase and tyrosine kinase inhibitors: A series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-R?, and histone deacetylases. J. Med. Chem., 52, 2265–2279 (2009).PubMedCrossRefGoogle Scholar
- Mahboobi, S., Sellmer, A., Winkler, M., Eichhorn, E., Pongratz, H., Ciossek, T., Baer, T., Maier, T., and Beckers, T., Novel chimeric histone deacetylase inhibitors: A series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity. J. Med. Chem., 53, 8546–8555 (2010).PubMedCrossRefGoogle Scholar
- Vizirianakis, I. S., Chatzopoulou, M., Bonovolias, I. D., Nicolaou, I., Demopoulos, V. J., and Tsiftsoglou, A. S., Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives. J. Med. Chem., 53, 6779–6810 (2010).PubMedCrossRefGoogle Scholar